Q1 2026 Earnings Estimate for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research lowered their Q1 2026 EPS estimates for shares of Esperion Therapeutics in a research note issued on Monday, May 6th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn $0.40 per share for the quarter, down from their prior estimate of $0.51. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

ESPR has been the subject of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Stock Down 13.9 %

Shares of ESPR stock opened at $2.04 on Tuesday. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The stock has a market capitalization of $386.38 million, a PE ratio of -0.96 and a beta of 0.89. The firm has a 50 day moving average of $2.31 and a two-hundred day moving average of $2.07.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the business earned ($0.76) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Wasatch Advisors LP increased its stake in shares of Esperion Therapeutics by 2.7% during the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after acquiring an additional 238,544 shares during the period. Armistice Capital LLC purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $9,568,000. Monaco Asset Management SAM boosted its holdings in Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 476,477 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Esperion Therapeutics by 1.0% during the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock worth $3,373,000 after buying an additional 11,494 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Esperion Therapeutics by 120.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 225,767 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.